PTx is a biopharmaceutical company focused on developing and commercializing therapies for cancer, utilizing targeted treatments like BIZENGRI® (zenocutuzumab-zbco) to improve patient outcomes. The company addresses the need for effective options in oncology by partnering with medical and scientific communities to expand treatment possibilities for serious diseases.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack targeted therapies, resulting in limited treatment options and poor outcomes for patients with specific genetic mutations or protein overexpression. The need for effective therapies is particularly acute in cancers where existing treatments have limited efficacy or significant side effects.
Solution
Partner Therapeutics (PTx) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. Their lead product, BIZENGRI® (zenocutuzumab-zbco), is designed to address specific molecular targets within cancer cells, aiming to improve patient outcomes by selectively interfering with tumor growth and spread. PTx partners with medical and scientific communities to expand treatment possibilities for serious diseases, focusing on areas of unmet medical need in oncology. By concentrating on targeted treatments, PTx seeks to provide more effective and less toxic options for patients battling cancer.
Target Audience
The primary target audience includes patients with cancers that express the specific molecular target of BIZENGRI®, as well as oncologists and other healthcare professionals seeking more effective treatment options for these patients.
Features
- BIZENGRI® (zenocutuzumab-zbco): A targeted therapy designed to address specific molecular targets in cancer cells.
- Focus on developing and commercializing therapies for cancers with limited treatment options.
- Partnerships with medical and scientific communities to expand treatment possibilities.
- Commitment to addressing unmet medical needs in oncology.